help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verde, G. G.
Right arrow Articles by Liuzzi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verde, G. G.
Right arrow Articles by Liuzzi, A.

Journal of Clinical Endocrinology & Metabolism, Vol 63, 1406-1410, Copyright © 1986 by Endocrine Society

ARTICLES

Serum type III procollagen propeptide levels in acromegalic patients

GG Verde, I Santi, P Chiodini, R Cozzi, D Dallabonzana, G Oppizzi and A Liuzzi

Serum type III procollagen propeptide (PIIIP) is a reliable index of tissue collagen synthesis. Since in acromegaly there is increased collagen production, we measured serum PIIIP in acromegalic patients before any treatment (basal), during medical treatment with the somatostatin analog SMS 201-995, and after pituitary adenomectomy. In all patients, serum GH and plasma somatomedin-C (SmC) levels were also measured. Basal serum PIIIP levels were significantly (P less than 0.01) higher in acromegalic patients (mean +/- SEM, 22.7 +/- 2.1 ng/ml) than in normal subjects (n = 30; 9.7 +/- 0.5 ng/ml), and they were significantly correlated with plasma SmC values (r = 0.31; P less than 0.05). A significant (P less than 0.01) reduction in PIIIP levels occurred in patients treated with SMS 201-995 or surgery (from 24.3 +/- 2.7 to 12.4 +/- 1 ng/ml) as well as in GH and SmC levels. The maximum percent decrease in serum PIIIP was significantly correlated with those in GH (r = 0.65; P less than 0.01) and SmC (r = 0.60; P less than 0.01). Serum PIIIP levels did not change in those patients in whom neither GH nor SmC were decreased by treatment. In conclusion, serum PIIIP levels are elevated in acromegalic patients, and they decline in parallel with GH and SmC during medical or surgical treatment. Serum PIIIP measurements may be useful in the evaluation of acromegalic patients to gain information on the biological activity of GH and in monitoring the course of the disease.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
S. Longobardi, N. Keay, C. Ehrnborg, A. Cittadini, T. Rosén, R. Dall, M. A. Boroujerdi, E. E. Bassett, M. L. Healy, C. Pentecost, et al.
Growth Hormone (GH) Effects on Bone and Collagen Turnover in Healthy Adults and Its Potential as a Marker of GH Abuse in Sports: A Double Blind, Placebo-Controlled Study
J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1505 - 1512.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. D. Wallace, R. C. Cuneo, P. A. Lundberg, T. Rosén, J. O. L. Jørgensen, S. Longobardi, N. Keay, L. Sacca, J. S. Christiansen, B.-A. Bengtsson, et al.
Responses of Markers of Bone and Collagen Turnover to Exercise, Growth Hormone (GH) Administration, and GH Withdrawal in Trained Adult Males
J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 124 - 133.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society